Glax­o­SmithK­line's vac­cines group aims for a first as it kicks off PhI­II RSV stud­ies

One of Glax­o­SmithK­line’s big projects at its glob­al vac­cine R&D cen­ter in Rockville, MD is set to en­ter Phase III af­ter pass­ing ear­ly-stage tests with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.